CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Oxytocin

催产素 杂质对照品Oxytocin Impurities

EP19 个杂质条目19 impurity entries

本页汇总 催产素 的 19 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 19 impurity reference standards of Oxytocin with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 催产素(Oxytocin)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesPhotodegradation of oxytocin and thermal stability of photoproducts
    Journal of pharmaceutical sciences · 2012 · Mozziconacci O, Schöneich C  ·  PMID 22623074  ·  DOI
  2. 杂质研究Impurity studiesRapid and sensitive fluorescence determination of oxytocin using nitrogen-doped carbon dots as fluorophores
    Journal of pharmaceutical and biomedical analysis · 2023 · Zhou Y et al.  ·  PMID 36966622  ·  DOI
  3. 杂质研究Impurity studiesEffect of 18-Crown-6 on Oxytocin Stability in Aqueous Buffer Solutions
    ACS omega · 2021 · Ghasemisarabbadieh M et al.  ·  PMID 33681619  ·  DOI
  4. 分析方法Analytical MethodsLiquid chromatographic analysis of oxytocin and its related substances
    Journal of pharmaceutical and biomedical analysis · 2010 · Ashenafi D et al.  ·  PMID 19716673  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisOxytocin and pain: a systematic review and synthesis of findings
    The Clinical journal of pain · 2014 · Rash JA et al.  ·  PMID 23887343  ·  DOI

催产素 —— 原料药与杂质对照品Oxytocin — drug substance & impurities

共 20 个条目(含原料药本体)20 items incl. the drug substance
Oxytocin structure
EP原料药 APIAPIPeptide
催产素Oxytocin
Oxytocin
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2
CAS No.50-56-6
Chemical FormulaC43H66N12O12S2
Purity>95%询价On request
10mg25mg50mg100mg
Oxytocin Impurity 2 (Oxytocin EP Impurity B) structure
EPB
催产素杂质2 (催产素EP杂质B)Oxytocin Impurity 2 (Oxytocin EP Impurity B)
Oxytocin Impurity 2 (Oxytocin EP Impurity B)
CAS No.20054-93-7
Chemical FormulaC86H132N24O24S4
Purity>95%询价On request
10mg25mg50mg100mg
Oxytocin Impurity 7 (Oxytocin EP Impurity C) (Glu4 Oxytocin) structure
EPC
催产素杂质7 (催产素EP杂质C) (谷氨酸4 催产素)Oxytocin Impurity 7 (Oxytocin EP Impurity C) (Glu4 Oxytocin)
Oxytocin Impurity 7 (Oxytocin EP Impurity C) (Glu4 Oxytocin)
CAS No.4314-67-4
Chemical FormulaC43H65N11O13S2
Purity>95%询价On request
10mg25mg50mg100mg
Oxytocin Impurity 8 (Oxytocin EP Impurity D) (Leu3 Oxytocin) structure
EPD
催产素杂质8 (催产素EP杂质D) (亮氨酸3 催产素)Oxytocin Impurity 8 (Oxytocin EP Impurity D) (Leu3 Oxytocin)
Oxytocin Impurity 8 (Oxytocin EP Impurity D) (Leu3 Oxytocin)
CAS No.4294-11-5
Chemical FormulaC43H66N12O12S2
Purity>95%询价On request
10mg25mg50mg100mg
Oxytocin Impurity 10 (Oxytocin EP Impurity E) structure
EPE
催产素杂质10 (催产素EP杂质E)Oxytocin Impurity 10 (Oxytocin EP Impurity E)
Oxytocin Impurity 10 (Oxytocin EP Impurity E)
CAS No.10551-48-1
Chemical FormulaC45H68N12O13S2
Purity>95%询价On request
10mg25mg50mg100mg
Oxytocin Impurity 29 (Oxytocin EP Impurity F) structure
EPF
催产素杂质29 (催产素EP杂质 F)Oxytocin Impurity 29 (Oxytocin EP Impurity F)
Oxytocin Impurity 29 (Oxytocin EP Impurity F)
CAS No.87590-89-4
Chemical FormulaC43H64N12O11S2
Purity>95%询价On request
10mg25mg50mg100mg
Oxytocin Impurity 6 (Oxytocin EP Impurity I ) structure
EPI
催产素杂质6 (催产素EP杂质I)Oxytocin Impurity 6 (Oxytocin EP Impurity I )
Oxytocin Impurity 6 (Oxytocin EP Impurity I )
CAS No.65907-78-0
Chemical FormulaC43H65N11O13S2
Purity>95%询价On request
10mg25mg50mg100mg
Oxytocin Impurity 4 structure
4
催产素杂质4Oxytocin Impurity 4
Oxytocin Impurity 4
CAS No.6390-51-8
Chemical FormulaC48H74N12O14S2
Purity>95%询价On request
10mg25mg50mg100mg
Oxytocin Impurity 5 Monomer structure
5
催产素杂质5 单体Oxytocin Impurity 5 Monomer
Oxytocin Impurity 5 Monomer
CAS No.4248-64-0
Chemical FormulaC43H65N11O13S2
Purity>95%询价On request
10mg25mg50mg100mg
Oxytocin Impurity 12 (Gly7 Oxytocin) structure
12
催产素杂质12 (甘氨酸7 催产素)Oxytocin Impurity 12 (Gly7 Oxytocin)
Oxytocin Impurity 12 (Gly7 Oxytocin)
CAS No.19748-53-9
Chemical FormulaC40H62N12O12S2
Purity>95%询价On request
10mg25mg50mg100mg
Oxytocin Impurity 13(Des Gly9 Oxytocin) structure
13
催产素杂质13 (去甘氨酸9 催产素)Oxytocin Impurity 13(Des Gly9 Oxytocin)
Oxytocin Impurity 13(Des Gly9 Oxytocin)
CAS No.4294-07-9
Chemical FormulaC41H62N10O12S2
Purity>95%询价On request
10mg25mg50mg100mg
Oxytocin Impurity 17 (Endo Gly9 Oxytocin) structure
17
催产素杂质17 (Endo 甘氨酸9 催产素)Oxytocin Impurity 17 (Endo Gly9 Oxytocin)
Oxytocin Impurity 17 (Endo Gly9 Oxytocin)
CAS No.21687-84-3
Chemical FormulaC45H69N13O13S2
Purity>95%询价On request
10mg25mg50mg100mg
Oxytocin Impurity 18 (Glu3 Asp4 Oxytocin) structure
18
催产素杂质18 (谷氨酸3 天冬氨酸4 催产素)Oxytocin Impurity 18 (Glu3 Asp4 Oxytocin)
Oxytocin Impurity 18 (Glu3 Asp4 Oxytocin)
CAS No.2092497-01-1
Chemical FormulaC43H64N10O14S2
Purity>95%询价On request
10mg25mg50mg100mg
Oxytocin Impurity 19(D-Asn5 Oxytocin) structure
19
催产素杂质19 (D-天冬酰胺5 催产素)Oxytocin Impurity 19(D-Asn5 Oxytocin)
Oxytocin Impurity 19(D-Asn5 Oxytocin)
CAS No.5754-53-0
Chemical FormulaC43H66N12O12S2
Purity>95%询价On request
10mg25mg50mg100mg
Oxytocin Impurity 20 (Dihydrooxytocin) structure
20
催产素杂质20 (二氢催产素)Oxytocin Impurity 20 (Dihydrooxytocin)
Oxytocin Impurity 20 (Dihydrooxytocin)
CAS No.17912-60-6
Chemical FormulaC43H68N12O12S2
Purity>95%询价On request
10mg25mg50mg100mg
Oxytocin Impurity 28 structure
28
催产素杂质28Oxytocin Impurity 28
Oxytocin Impurity 28
CAS No.186798-41-4
Chemical FormulaC43H66N12O12S3
Purity>95%询价On request
10mg25mg50mg100mg
Oxytocin Impurity 30 structure
30
催产素杂质30Oxytocin Impurity 30
Oxytocin Impurity 30
CAS No.959359-23-0
Chemical FormulaC43H65N11O12S2
Purity>95%询价On request
10mg25mg50mg100mg
Oxytocin Impurity 31 (Des Gly9 Oxytocin) structure
31
催产素杂质31 (去甘氨酸9 催产素)Oxytocin Impurity 31 (Des Gly9 Oxytocin)
Oxytocin Impurity 31 (Des Gly9 Oxytocin)
CAS No.13018-25-2
Chemical FormulaC41H63N11O11S2
Purity>95%询价On request
10mg25mg50mg100mg
Oxytocin Impurity 36 structure
36
催产素杂质36Oxytocin Impurity 36
Oxytocin Impurity 36
CAS No.43157-23-9
Chemical FormulaC46H65N13O11S2
Purity>95%询价On request
10mg25mg50mg100mg
Oxytocin Impurity 39 (2-(3-Nitro-L-Tyrosine)Oxytocin) structure
39
催产素杂质39 (2-(3-硝基-L-酪氨酸)催产素)Oxytocin Impurity 39 (2-(3-Nitro-L-Tyrosine)Oxytocin)
Oxytocin Impurity 39 (2-(3-Nitro-L-Tyrosine)Oxytocin)
CAS No.34693-72-6
Chemical FormulaC43H65N13O14S2
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

催产素 —— 研究文献与合成路线Oxytocin — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 催产素 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Oxytocin. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Towards heat-stable oxytocin formulations: analysis of degradation kinetics and identification of degradation products
    Hawe A, Poole R, Romeijn S, et al. · Pharmaceutical research · 2009 · 被引 56cited 56
  2. Formation of amide- and imide-linked degradation products between the peptide drug oxytocin and citrate in citrate-buffered formulations
    Poole RA, Kasper PT, Jiskoot W · Journal of pharmaceutical sciences · 2011 · 被引 19cited 19
  3. Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation
    Engstrøm T, Barth T, Melin P, et al. · European journal of pharmacology · 1998 · 被引 56cited 56
  4. Structurally related peptide impurity identification and accurate quantification for synthetic oxytocin by liquid chromatography-high-resolution mass spectrometry
    Li M, Josephs RD, Daireaux A, et al. · Analytical and bioanalytical chemistry · 2021 · 被引 13cited 13
  5. Capillary electrophoresis separation of the desamino degradation products of oxytocin
    Creamer JS, Krauss ST, Lunte SM · Electrophoresis · 2014 · 被引 7cited 7
  6. Alkylation of oxytocin by S-(2-chloroethyl)glutathione and characterization of adducts by tandem mass spectrometry and Edman degradation
    Erve JC, Deinzer ML, Reed DJ · Chemical research in toxicology · 1995 · 被引 7cited 7

合成与制备工艺专利Synthesis & process patents

  1. Preparing process for synthesizing oxytocin from solid-phase polypeptide
    ZHOU YIMING · 公开号 CN1990501CN1990501 · 2007
  2. Method for preparing oxytocin
    YONGPING WU · 公开号 CN101235081CN101235081 · 2008
  3. SUBSTITUTED DIKETOPIPERAZINES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE PREPARATION OF MEDICAMENTS FOR ANTAGONIZING THE EFFECTS OF OXYTOCIN ON THE OXYTOCIN RECEPTOR
    — · 公开号 IL172529IL172529 · 2011
  4. USE OF SUBSTANCES HAVING OXYTOCIN ANTAGONISTIC PROPERTIES FOR THE PREPARATION OF A MEDICAMENT FOR TREATING HYPERTENSION
    REINHEIMER TORSTEN MICHAEL, GARFIELD ROBERT EDWARD · 公开号 CA2544495CA2544495 · 2005
  5. Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension
    EDWARD REINHEIMER TORSTEN MICH · 公开号 CN1909917CN1909917 · 2007

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

催产素 杂质谱研究要点Oxytocin — impurity profiling notes

下面这些是拿到 催产素 的 20 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 20 impurity entries for Oxytocin, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances